Oncolytics Biotech Completes Initial Scale Up of Manufacturing Process for REOLYSIN® to Commercial Scale

News   Oct 15, 2008

 
Oncolytics Biotech Completes Initial Scale Up of Manufacturing Process for REOLYSIN® to Commercial Scale
 
 
 

RELATED ARTICLES

PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug Discovery

News

Investment to fund expansion of operations and progression of drug target pipeline.

READ MORE

Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing Sites

News

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

READ MORE

Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine

News

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE